| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Paradigm Biocapital Advisors LP | 9% | +80% | $84,110,876 | +$37,586,159 | 4,216,084 | +81% | Paradigm BioCapital Advisors LP | 30 Sep 2025 |
| MORGAN STANLEY | 5.4% | +180% | $35,433,378 | +$24,712,637 | 2,488,299 | +231% | Morgan Stanley | 30 Jun 2025 |
| MENORA MIVTACHIM HOLDINGS LTD. | 5% | $24,780,614 | 2,303,031 | Menora Mivtachim Holdings Ltd | 11 Mar 2025 | |||
| TORONTO DOMINION BANK | 4.9% | -29% | $45,655,283 | -$17,612,530 | 2,302,334 | -28% | The Toronto-Dominion Bank | 31 Dec 2025 |
| BlackRock, Inc. | 5% | $31,292,937 | 2,284,206 | BlackRock, Inc. | 30 Jun 2025 | |||
| Soleus Capital Master Fund, L.P. | 4.7% | -6% | $31,114,400 | -$1,993,600 | 2,185,000 | -6% | Soleus Capital Master Fund, L.P. | 30 Jun 2025 |
| Adage Capital Management, L.P. | 2.8% | -60% | $13,740,520 | -$17,765,685 | 1,277,000 | -56% | Adage Capital Management, L.P. | 31 Mar 2025 |
| Monograph Capital Holdings Advisors, LLC | 1.8% | $8,503,556 | 838,615 | Monograph Capital Partners I, L.P. | 05 Jun 2025 |
As of 31 Dec 2025, 165 institutional investors reported holding 43,701,140 shares of UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (URGN). This represents 93% of the company’s total 46,986,408 outstanding shares.
The largest institutional shareholders of UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (URGN) together control 74% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| RTW INVESTMENTS, LP | 9.7% | 4,543,895 | 0% | 1.1% | $106,418,021 |
| Paradigm Biocapital Advisors LP | 9.5% | 4,473,648 | +6.1% | 2.8% | $104,772,836 |
| BlackRock, Inc. | 5.5% | 2,601,009 | +0.76% | 0% | $60,915,631 |
| MORGAN STANLEY | 5.5% | 2,562,901 | +1.4% | 0% | $60,023,155 |
| Jefferies Financial Group Inc. | 4.7% | 2,199,652 | 0% | 0.42% | $51,515,850 |
| SILVERARC CAPITAL MANAGEMENT, LLC | 3.7% | 1,738,821 | +10% | 5.9% | $40,723,188 |
| ACORN CAPITAL ADVISORS, LLC | 3.1% | 1,448,420 | +15% | 11% | $33,921,996 |
| SG Americas Securities, LLC | 2.9% | 1,377,647 | +19% | 0.04% | $32,264,000 |
| AMERICAN CENTURY COMPANIES INC | 2.9% | 1,358,812 | 0.02% | $31,823,425 | |
| MENORA MIVTACHIM HOLDINGS LTD. | 2.5% | 1,152,531 | 0% | 0.13% | $26,992,276 |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | 2.4% | 1,125,100 | 0.04% | $26,349,842 | |
| D. E. Shaw & Co., Inc. | 2% | 962,624 | +8.3% | 0.02% | $22,544,654 |
| MPM BIOIMPACT LLC | 2% | 941,378 | +597% | 2.5% | $22,047,073 |
| ORBIMED ADVISORS LLC | 1.9% | 875,487 | +27% | 0.44% | $20,503,906 |
| STATE STREET CORP | 1.7% | 807,421 | -1.5% | 0% | $18,909,800 |
| FRONTIER CAPITAL MANAGEMENT CO LLC | 1.7% | 781,620 | 0.19% | $18,305,546 | |
| Migdal Insurance & Financial Holdings Ltd. | 1.6% | 770,909 | 0% | 0.16% | $18,055,000 |
| CITADEL ADVISORS LLC | 1.6% | 737,757 | +22% | 0.01% | $17,278,269 |
| SUPERSTRING CAPITAL MANAGEMENT LP | 1.5% | 718,354 | +717% | 9% | $16,823,851 |
| TCG Crossover Management, LLC | 1.5% | 717,347 | 0% | 0.56% | $16,800,267 |
| MILLENNIUM MANAGEMENT LLC | 1.3% | 618,952 | -58% | 0.01% | $14,495,856 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 1.3% | 616,606 | +73% | 0% | $14,441,000 |
| J. Goldman & Co LP | 1.1% | 513,303 | 0.47% | $12,021,556 | |
| Woodline Partners LP | 1.1% | 500,726 | +63% | 0.05% | $11,727,003 |
| Boxer Capital Management, LLC | 1.1% | 500,000 | -13% | 2.6% | $11,710,000 |
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 43,701,140 | $1,023,353,242 | +$14,743,525 | $23.42 | 165 |
| 2025 Q3 | 43,904,765 | $877,180,169 | +$94,297,658 | $19.95 | 159 |
| 2025 Q2 | 39,798,464 | $545,161,051 | +$3,475,596 | $13.70 | 149 |
| 2025 Q1 | 41,643,932 | $460,619,197 | +$59,835,372 | $11.06 | 139 |
| 2024 Q4 | 36,306,231 | $386,611,717 | -$9,614,830 | $10.65 | 139 |
| 2024 Q3 | 35,097,143 | $445,735,362 | -$58,506,168 | $12.70 | 127 |
| 2024 Q2 | 38,225,503 | $641,423,803 | +$207,327,873 | $16.78 | 114 |
| 2024 Q1 | 27,162,024 | $407,381,837 | +$84,866,378 | $15.00 | 111 |
| 2023 Q4 | 21,390,291 | $320,854,510 | +$51,912,609 | $15.00 | 103 |
| 2023 Q3 | 17,724,118 | $248,330,352 | +$65,704,038 | $14.01 | 100 |
| 2023 Q2 | 13,209,673 | $136,728,106 | +$7,180,182 | $10.35 | 84 |
| 2023 Q1 | 12,428,895 | $114,822,764 | -$4,446,429 | $9.24 | 64 |
| 2022 Q4 | 13,022,042 | $115,449,037 | -$2,381,858 | $8.87 | 63 |
| 2022 Q3 | 13,319,758 | $110,811,074 | -$981,981 | $8.32 | 56 |
| 2022 Q2 | 13,444,839 | $109,243,080 | -$6,040,297 | $8.19 | 60 |
| 2022 Q1 | 14,223,995 | $123,920,902 | +$1,868,931 | $8.71 | 82 |
| 2021 Q4 | 14,650,914 | $139,360,752 | +$2,176,410 | $9.51 | 71 |
| 2021 Q3 | 14,085,432 | $236,906,894 | +$1,235,828 | $16.82 | 88 |
| 2021 Q2 | 13,993,075 | $213,691,867 | -$5,527,357 | $15.27 | 78 |
| 2021 Q1 | 14,299,652 | $278,497,797 | -$4,203,728 | $19.48 | 88 |
| 2020 Q4 | 14,549,849 | $261,548,580 | -$10,506,654 | $18.02 | 81 |
| 2020 Q3 | 15,009,007 | $288,527,801 | +$6,244,867 | $19.29 | 78 |
| 2020 Q2 | 14,672,947 | $381,998,824 | +$28,263,022 | $26.12 | 83 |
| 2020 Q1 | 13,991,634 | $249,248,555 | -$10,038,151 | $17.84 | 78 |
| 2019 Q4 | 14,182,815 | $472,998,729 | +$4,841,998 | $33.37 | 85 |
| 2019 Q3 | 14,565,725 | $346,785,326 | -$26,211,624 | $23.83 | 83 |
| 2019 Q2 | 14,681,109 | $527,197,234 | +$43,911,794 | $35.94 | 84 |
| 2019 Q1 | 13,462,231 | $497,232,334 | +$142,583,669 | $36.94 | 73 |
| 2018 Q4 | 9,585,700 | $412,953,000 | +$18,631,256 | $43.06 | 63 |
| 2018 Q3 | 9,922,967 | $468,843,000 | +$14,656,634 | $47.23 | 70 |
| 2018 Q2 | 9,602,369 | $482,439,000 | +$24,129,548 | $49.76 | 60 |
| 2018 Q1 | 9,137,601 | $454,036,000 | +$118,577,913 | $49.69 | 43 |
| 2017 Q4 | 5,741,200 | $213,691,000 | +$83,149,343 | $37.21 | 40 |
| 2017 Q3 | 3,121,706 | $98,400,000 | +$1,688,330 | $31.52 | 29 |
| 2017 Q2 | 4,717,310 | $85,197,000 | +$85,197,000 | $18.06 | 21 |